| Nov 5 |
Editas Q3 Loss Narrower Than Expected, Revenues Decrease Y/Y
|
| Nov 5 |
Is Novartis (NVS) Stock Undervalued Right Now?
|
| Nov 5 |
Is Argenx (ARGX) Outperforming Other Medical Stocks This Year?
|
| Nov 4 |
Zoetis Q3 Earnings & Revenues Beat, '24 Outlook Raised, Stock Up
|
| Nov 2 |
Novartis CEO 'very confident' on sales target, doesn't fear patent cliff - newspaper
|
| Nov 1 |
Pharma Stock Roundup: MRK, PFE, ABBV, NVS, LLY's Q3 Earnings in Focus
|
| Nov 1 |
Madrigal Q3 Earnings Beat, NASH Drug Sales Drive Top Line, Stock Up
|
| Nov 1 |
Alnylam Q3 Loss In Line With Estimates, Revenues Miss, Stock Down
|
| Oct 31 |
REGN Q3 Earnings and Revenues Beat on Strong Eylea HD & Dupixent Sales
|
| Oct 30 |
Positive Outlook For Novartis As Company Capitalizes On Growing Treatment Opportunities, Analyst Highlights
|
